SG Americas Securities
ANIX icon

SG Americas Securities’s Anixa Biosciences ANIX Stock Holding History

SG Americas Securities’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,514
Closed -$44K – 2917
2025
Q1 		$44K Buy
+15,514
New +$44.4K ﹤0.01% 3261
2019
Q2 		– Sell
-101,616
Closed -$459K – 3054
2019
Q1 		$459K Buy
+101,616
New +$484K ﹤0.01% 1913

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MWM
Mission Wealth Management Santa Barbara, California $4.86B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

SG Americas Securities's ANIX Position: Q2 2025 in Review

SG Americas Securities sold out of Anixa Biosciences (ANIX) in Q2 2025, closing a stake of 15,514 shares — an estimated $44K sold.

SG Americas Securities first reported a position in ANIX in Q1 2019 and held it in 2 quarters. The position peaked at $459K in Q1 2019. 66 funds tracked by Wall St. Rank hold ANIX as of Q2 2025.

  • SG Americas Securities reported no remaining Anixa Biosciences position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 15,514 Anixa Biosciences shares in Q2 2025, an estimated $44K.
  • SG Americas Securities first reported a position in Anixa Biosciences in Q1 2019 and held it in 2 quarters.
  • SG Americas Securities's Anixa Biosciences position peaked at $459K in Q1 2019.
  • 66 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.